| 主权项 |
1. A crystalline Cabazitaxel alkyl acetate solvate selected from:
a) Crystalline Cabazitaxel ethyl acetate solvate, designated as Form VII, characterized by data selected from one or more of the following: a powder X-ray diffraction pattern having peaks at 7.9, 8.6, 10.0, 10.2 and 15.8 degrees two theta±0.1 degrees two theta, and also having no peak in the area from 10.5 to 12.1 degrees two theta; a powder X-ray diffraction pattern as depicted in FIG. 1; or combinations of these data; b) Crystalline isopropyl acetate solvate of cabazitaxel, designated as Form VIII, characterized by data selected from one or more of the following: a powder X-ray diffraction pattern having peaks at 7.9, 8.6, 10.0, 10.2 and 16.6 degrees two theta±0.1 degrees two theta, and also having no peak in the area from 10.5 to 12.1 degrees two theta; a powder X-ray diffraction pattern as depicted in FIG. 4; or a combination of these data; c) Crystalline Cabazitaxel methyl acetate solvate, designated as Form XVII, characterized by data selected from one or more of the following: a powder X-ray diffraction pattern having peaks at 8.0, 8.7, 14.2, 15.1 and 15.9 degrees two theta±0.1 degrees two theta; a powder X-ray diffraction pattern as depicted in FIG. 37; or combination of these data; d) Crystalline Cabazitaxel butyl acetate solvate, designated as Form XVIII, characterized by data selected from: a powder X-ray diffraction pattern having peaks at 8.6, 13.6, 14.0, 19.2 and 19.8 degrees two theta±0.1 degrees two theta; a powder X-ray diffraction pattern as depicted in FIG. 40; or a combination of these data; or e) Crystalline Cabazitaxel isobutyl acetate, designated as Form XXI, characterized by data selected from one or more of the following: a powder X-ray diffraction pattern having peaks at 8.6, 14.0, 15.6, 16.3 and 19.6 degrees two theta±0.1 degrees two theta; a powder X-ray diffraction pattern as depicted in FIG. 49; or a combination of these data. |
